
Performance · Recovery · Longevity
Catalogue
Browse “Muscle/Performamnce, Recovery/Tissue, Weight Loss/Metabolic and Research Peptides“ and advanced wellness compounds. Prices are shown in South African Rand (ZAR).
Select a product to view available quantities, specifications and regulatory status. Quantities, documentation and pricing are confirmed before dispatch.
BPC-157 (UPA Platinum)
|
Category: |
Recovery / Tissue |
|
SKU: |
TRW-BPC157 |
|
Price: |
R 400.00 |
|
{{variant.name}}:
|
{{opt.name}}
{{opt.name}}
|
TEST RUN WELLNESS BPC-157 5 | 5mg Regenerative Pentadecapeptide (Self-Mix Vial)
BPC-157 5mg – Synthetic pentadecapeptide analogue of a partial sequence of human gastric juice protein BPC, supplied as a lyophilised powder for reconstitution. A stable 15-amino-acid sequence studied for site-specific soft-tissue repair, gastrointestinal mucosal integrity and anti-inflammatory recovery support. Includes 2 ml bacteriostatic water.
Product Overview
BPC-157 is a synthetic pentadecapeptide — 15 amino acids, sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular mass approximately 1 419 Da. It is a stable analogue of a partial sequence of the BPC protein naturally present in human gastric juice, from which the "Body Protection Compound" designation derives.
The molecule is not a hormone and does not bind classical endocrine receptors. Its described activity is broad and upstream of the healing cascade, converging on angiogenesis, growth factor receptor expression and nitric oxide signalling. This breadth — rather than selectivity for a single receptor — is the defining pharmacological characteristic of the compound and explains the unusually wide organ range reported in animal models.
BPC-157 is supplied here as a 5 mg lyophilised powder in a self-mix vial with 2 ml bacteriostatic water. Reconstitution at the full 2 ml yields a concentration of 2 500 mcg/ml. Because the peptide is a short, unprotected sequence, it is susceptible to enzymatic degradation in plasma; no human pharmacokinetic data — absorption, distribution, half-life or clearance — are established for any route of administration.
How BPC-157 Works: Angiogenesis and Cytoprotective Signalling Pathway
BPC-157 has no single defined receptor target. Its reported mechanism is a set of convergent interactions with vascular, growth factor and neurotransmitter signalling systems.
The most consistently described pathway is activation of vascular endothelial growth factor receptor 2 (VEGFR2) and the downstream Akt–endothelial nitric oxide synthase (eNOS) axis. Receptor activation initiates endothelial cell migration, proliferation and tube formation, producing new capillary growth in tissue beds with poor baseline perfusion.
This is the mechanistic basis proposed for its effect at tendon–bone junctions, which are characteristically hypovascular and heal slowly for that reason.
In parallel, BPC-157 is reported to upregulate the expression of growth factor receptors — including VEGFR2 and epidermal growth factor receptor (EGFR) — in tendon fibroblasts and other cell types.
The peptide does not supply exogenous growth factor; it increases local responsiveness to endogenous growth factors already present. Modulation of the FAK–paxillin and ERK pathways involved in fibroblast migration and cytoskeletal reorganisation has also been described.
BPC-157 interacts with both the L-arginine–nitric oxide and the L-NAME-inhibitable components of the NO system, and has been reported to counteract the effects of nitric oxide synthase blockade. This NO system interaction is the proposed basis for the cytoprotective and vasoactive effects observed across multiple organ systems in animal models.
Rodent work additionally describes counteraction of dopamine antagonist and reserpine-induced lesions, together with modulation of serotonin release in the gastrointestinal tract, as contributors to the gut-protective profile.Because the peptide is a fragment of a protein naturally present in gastric juice, its described function is maintenance of biological homeostasis and mucosal defence rather than stimulation of any one repair pathway.
The majority of this mechanism data derives from rodent and in vitro models, frequently using parenteral or intraperitoneal routes that do not map directly to human subcutaneous use. No human pharmacokinetic study exists, no human half-life has been established, and dose–response relationships in humans are not characterised. Mechanistic findings should therefore be treated as preclinical.
Body Recomposition Benefits
BPC-157's described benefits are reparative and structural rather than anabolic. The compound drives no increase in protein synthesis and has no activity at the androgen receptor.
In research models, BPC-157 has been used to study accelerated healing of induced tendon, ligament and muscle injury, with reported improvements in fibroblast recruitment, collagen organisation and restored tensile strength at tendon–bone junctions.
Rat models of Achilles tendon, medial collateral ligament and patellar tendon transection — typically at doses in the region of 10 mcg/kg daily — form the strongest and most reproducible part of the preclinical literature. In a training context, the intended outcome is a shortened time-to-return after a strain rather than an increase in peak contractile capacity.
BPC-157 has one of the widest preclinical datasets of any peptide in gastrointestinal research: protection against ethanol-, NSAID- and stress-induced gastric and duodenal lesions, acceleration of ulcer and anastomosis healing, reduced intestinal inflammation and reported benefit in models of inflammatory bowel disease and short-bowel syndrome.
Improved gut integrity is relevant to body composition indirectly, through nutrient tolerance and absorption, rather than through any direct metabolic effect.
Reported anti-inflammatory activity — reduced pro-inflammatory cytokine expression and counteraction of acute and chronic inflammatory injury in animal models — supports faster resolution of inflammation between training sessions. Rodent models of induced arthritis describe reduced joint swelling and preserved cartilage architecture.
Titration Protocol
BPC-157 is administered via subcutaneous injection. It is a single daily protocol, titrated by indication severity rather than by body weight. The compound has no validated human dose–response curve; all figures below are empirical and drawn from reported practice.
A standard titration schedule is as follows:
· General recovery: 0.25 – 0.5 mg daily (0.10 – 0.20 ml reconstituted) — joint health and gut repair
· Moderate injury: 0.5 – 1.0 mg daily (0.20 – 0.40 ml reconstituted) — tendon and ligament healing
· Chronic injury: 1.0 – 2.0 mg daily (0.40 – 0.80 ml reconstituted) — deep tissue and long-term recovery
· Cycle completion: 4–6 weeks of reported practitioner protocols, followed by a break of similar length before repeat cycling.
Volume figures assume reconstitution of the full 5 mg vial with the included 2 ml bacteriostatic water, giving 2 500 mcg/ml. One 5 mg vial reconstituted at 2 ml provides ten 0.5 mg doses or five 1.0 mg doses; plan vial use against the intended dose level before reconstituting.
Subcutaneous administration into abdominal or thigh fat is standard. For localised injury — tendinopathy, ligament or muscle tear — injection into subcutaneous tissue as close to the affected structure as is anatomically reasonable is the conventional approach; for gut or systemic indications, abdominal injection is used. Rotate sites between abdomen, thigh and upper arm. Do not inject into an acutely inflamed, infected or recently operated area.
Reconstitute by directing the diluent down the inside wall of the vial and swirling gently — do not shake, to avoid denaturing the peptide. Use a new insulin or 0.5-inch needle per injection and disinfect the vial septum and injection site with an alcohol swab. Inject at a 45–90° angle into pinched subcutaneous tissue. Store the lyophilised vial in a cool, dark place at 2–8 °C; store the reconstituted solution refrigerated at 2–8 °C, protected from light, and do not freeze it after reconstitution.
Dose escalation should only proceed if the current dose is well tolerated and the clinical response at 2–3 weeks is inadequate. There is no evidence that higher doses accelerate healing, and escalation increases systemic exposure without a corresponding demonstrated benefit. The published rodent literature more commonly uses twice-daily dosing; the once-daily human convention is a practical simplification, not a validated equivalence.
Combination Therapy
BPC-157 is commonly used as part of broader recovery and wellness protocols:
· BPC-157 + TB-500 (thymosin beta-4 fragment): The most widely used repair pairing, sometimes termed the "Wolverine stack." BPC-157 acts primarily on angiogenesis and local vascular supply, while TB-500 acts on actin sequestration and cell migration — described as complementary in mechanism and non-overlapping in receptor activity. Both peptides are prohibited in sport.
· BPC-157 + GHK-Cu (copper peptide): Targets dermal collagen and wound remodelling alongside deeper soft-tissue repair, typically in aesthetic and post-procedure recovery settings.
· BPC-157 + GH secretagogues (CJC-1295 with or without DAC, ipamorelin, tesamorelin): The rationale is that elevated pulsatile GH and IGF-1 provide systemic anabolic substrate while BPC-157 addresses the local structural deficit. This is a mechanistic argument only; combined use increases total injection burden and total unknown-exposure risk.
· BPC-157 + pentosan polysulfate or hyaluronic acid (intra-articular): Described in veterinary and limited human joint practice for osteoarthritis. Requires clinician administration and is not a self-administered protocol.
· BPC-157 + graded rehabilitation: The most defensible combination is pharmacological support alongside progressive loading and physiotherapy. Healing tissue requires mechanical stimulus, and no peptide substitutes for progressive load.
· Compounds that should not be assumed compatible: No interaction studies exist between BPC-157 and anticoagulants, antiplatelets, NSAIDs, corticosteroids or immunosuppressants. Given its VEGFR2/eNOS activity and reported effects on the NO system, concurrent anticoagulant or antiplatelet therapy warrants explicit clinical review before use.
Corticosteroid injection at the same anatomical site is generally discouraged concurrently, as the two interventions conflict in intent.
All combination approaches should be pursued under professional medical supervision.
Clinical Trial Record
BPC-157 was originally investigated in preclinical models of gastrointestinal ulceration and soft-tissue injury.
The preclinical record is where the majority of the evidence sits. Rat studies of induced Achilles tendon, medial collateral ligament and patellar tendon transection report accelerated healing and improved biomechanical strength at doses in the region of 10 mcg/kg daily.
Rodent muscle crush and transection models show accelerated functional recovery with reduced haematoma and oedema. The largest body of work concerns the gastrointestinal tract: protection against ethanol-, NSAID- and stress-induced gastric and duodenal lesions, accelerated anastomosis and ulcer healing, and benefit in colitis and short-bowel models.
Joint and cartilage models show reduced swelling and preserved cartilage architecture. Exploratory findings also exist for traumatic brain injury, peripheral nerve, liver, pancreatic and vascular models. In vitro work has demonstrated endothelial tube formation, fibroblast migration and VEGFR2/eNOS pathway activation in cell culture.
Technical Specifications
· Product Name: BPC-157 5
· Peptide: BPC-157 (pentadecapeptide, 15 amino acids)
· Concentration: 5mg per vial
· Form: Self-mix vial — lyophilised powder
· Reconstitution: Requires bacteriostatic water for reconstitution (2ml included)
· Reconstituted concentration: 2 500 mcg/ml (5mg in 2ml)
· Administration: Subcutaneous injection, once daily
· Storage: 2–8 °C, protected from light; do not freeze after reconstitution
· Regulatory Status: Not FDA-approved; not SAHPRA registered; research chemical
· Supplier: Test Run Wellness (Wellness.testrun)
⚕️ Important Medical Notice
Please consult your medical practitioner regarding your body requirements, as the dosing information provided contains guideline dosages. BPC-157 is intended for use under professional medical supervision.
Regulatory notice. Test Run Wellness is an independent supplier and is not the manufacturer of the products referenced. No product should be used without appropriate regulatory authorisation and professional medical oversight.